These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

168 related articles for article (PubMed ID: 27046950)

  • 21. Bone mineral density, bone turnover markers and fractures in patients with indolent systemic mastocytosis.
    Rossini M; Zanotti R; Bonadonna P; Artuso A; Caruso B; Schena D; Vecchiato D; Bonifacio M; Viapiana O; Gatti D; Senna G; Riccio A; Passalacqua G; Pizzolo G; Adami S
    Bone; 2011 Oct; 49(4):880-5. PubMed ID: 21782049
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Effect of low-dose alendronate treatment on bone mineral density and bone turnover markers in Chinese postmenopausal women with osteopenia and osteoporosis.
    Li M; Zhang ZL; Liao EY; Chen DC; Liu J; Tao TZ; Wu W; Xia WB; Lu YJ; Sheng ZF; Lu CY; Meng GL; Xu L; Zhang WJ; Hu YY; Xu L
    Menopause; 2013 Jan; 20(1):72-8. PubMed ID: 22968256
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Effectiveness of surgery and hyperbaric oxygen for antiresorptive agent-related osteonecrosis of the jaw: A subgroup analysis by disease stage.
    Watanabe T; Asai K; Fukuhara S; Uozumi R; Bessho K
    PLoS One; 2021; 16(1):e0244859. PubMed ID: 33395446
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Antiresorptive agent-related osteonecrosis of the jaw (ARONJ) in urological malignancies: a multi-center retrospective study.
    Sakai Y; Shindo T; Sato S; Takahashi A; Kunishima Y; Kato R; Itoh N; Okada M; Tachiki H; Taguchi K; Takayanagi A; Hotta H; Horita H; Matsukawa M; Matsuki M; Nishiyama K; Miyazaki A; Hashimoto K; Tanaka T; Masumori N
    J Bone Miner Metab; 2021 Jul; 39(4):661-667. PubMed ID: 33704573
    [TBL] [Abstract][Full Text] [Related]  

  • 25. The study of bone mineral density and bone turnover markers in postmenopausal women with active rheumatoid arthritis.
    Momohara S; Okamoto H; Yago T; Furuya T; Nanke Y; Kotake S; Soejima M; Mizumura T; Ikari K; Tomatsu T
    Mod Rheumatol; 2005; 15(6):410-4. PubMed ID: 17029104
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Serum N-telopeptide and bone-specific alkaline phosphatase levels in patients with osteonecrosis of the jaw receiving bisphosphonates for bone metastases.
    Morris PG; Fazio M; Farooki A; Estilo C; Mallam D; Conlin A; Patil S; Fleisher M; Cremers S; Huryn J; Hudis CA; Fornier MN
    J Oral Maxillofac Surg; 2012 Dec; 70(12):2768-75. PubMed ID: 22330331
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Clinical risk factors for severity and prognosis of antiresorptive agent-related osteonecrosis of the jaw: a retrospective observational study.
    Nashi M; Hirai T; Iwamoto T; Takenobu T
    J Bone Miner Metab; 2022 Nov; 40(6):1014-1020. PubMed ID: 36166107
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Histopathological findings affect quantitative values of single photon emission computed tomography in patients with antiresorptive agent-related osteonecrosis of the jaws.
    Okui T; Kobayashi Y; Isomura M; Tsujimoto M; Satoh K; Toyama H
    Fujita Med J; 2023 Aug; 9(3):186-193. PubMed ID: 37554942
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Anti-VEGFR therapy is one of the healing inhibitors of antiresorptive-related osteonecrosis of the jaw.
    Kanno C; Kaneko T; Endo M; Kitabatake T; Sakuma T; Kanaya Y; Watanabe Y; Hasegawa H
    J Bone Miner Metab; 2021 May; 39(3):423-429. PubMed ID: 33196901
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Differences in the capacity of several biochemical bone markers to assess high bone turnover in early menopause and response to alendronate therapy.
    Fink E; Cormier C; Steinmetz P; Kindermans C; Le Bouc Y; Souberbielle JC
    Osteoporos Int; 2000; 11(4):295-303. PubMed ID: 10928218
    [TBL] [Abstract][Full Text] [Related]  

  • 31. The relationship between regional bone turnover measured using 18F-fluoride positron emission tomography and changes in BMD is equivalent to that seen for biochemical markers of bone turnover.
    Frost ML; Cook GJ; Blake GM; Marsden PK; Fogelman I
    J Clin Densitom; 2007; 10(1):46-54. PubMed ID: 17289526
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Monitoring indices of bone inflammatory activity of the jaw using SPECT bone scintigraphy: a study of ARONJ patients.
    Hata H; Kitao T; Sato J; Asaka T; Ohga N; Imamachi K; Hirata K; Shiga T; Yamazaki Y; Kitagawa Y
    Sci Rep; 2020 Jul; 10(1):11385. PubMed ID: 32647190
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Short-term increases in bone turnover markers predict parathyroid hormone-induced spinal bone mineral density gains in postmenopausal women with glucocorticoid-induced osteoporosis.
    Lane NE; Sanchez S; Genant HK; Jenkins DK; Arnaud CD
    Osteoporos Int; 2000; 11(5):434-42. PubMed ID: 10912846
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Evaluation of ability of biochemical markers of bone turnover to predict a response to increased doses of HRT.
    Rosen HN; Parker RA; Greenspan SL; Iloputaife ID; Bookman L; Chapin D; Perlmutter I; Kessel B; Qvist P; Rosenblatt M
    Calcif Tissue Int; 2004 May; 74(5):415-23. PubMed ID: 14961215
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Serum BAP as the clinically useful marker for predicting BMD reduction in diabetic hemodialysis patients with low PTH.
    Ueda M; Inaba M; Okuno S; Maeno Y; Ishimura E; Yamakawa T; Nishizawa Y
    Life Sci; 2005 Jul; 77(10):1130-9. PubMed ID: 15978265
    [TBL] [Abstract][Full Text] [Related]  

  • 36. The predictive value of biochemical markers of bone turnover for bone mineral density in postmenopausal Japanese women.
    Chaki O; Yoshikata I; Kikuchi R; Nakayama M; Uchiyama Y; Hirahara F; Gorai I
    J Bone Miner Res; 2000 Aug; 15(8):1537-44. PubMed ID: 10934652
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Correlations between biochemical markers of bone turnover and bone density responses in patients with glucocorticoid-induced osteoporosis treated with teriparatide or alendronate.
    Burshell AL; Möricke R; Correa-Rotter R; Chen P; Warner MR; Dalsky GP; Taylor KA; Krege JH
    Bone; 2010 Apr; 46(4):935-9. PubMed ID: 20060081
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Reduced bone mineral density and increased bone turnover in Prader-Willi syndrome compared with controls matched for sex and body mass index--a cross-sectional study.
    Vestergaard P; Kristensen K; Bruun JM; Østergaard JR; Heickendorff L; Mosekilde L; Richelsen B
    J Pediatr; 2004 May; 144(5):614-9. PubMed ID: 15126995
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Bone mineral density in postmenarchal adolescent girls in the United States: associated biopsychosocial variables and bone turnover markers.
    Harel Z; Gold M; Cromer B; Bruner A; Stager M; Bachrach L; Wolter K; Reid C; Hertweck P; Nelson A; Nelson D; Coupey S; Johnson C; Burkman R; Bone H
    J Adolesc Health; 2007 Jan; 40(1):44-53. PubMed ID: 17185205
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Bone metabolism in postmenopausal women with lumbar spinal stenosis: analysis of bone mineral density and bone turnover markers.
    Kim HJ; Lee HM; Kim HS; Park JO; Moon ES; Park H; Park SY; Moon SH
    Spine (Phila Pa 1976); 2008 Oct; 33(22):2435-9. PubMed ID: 18923320
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.